122ACTIVITIES
1ORGS REPRESENTED
38BILLS
Organizations represented
1Orgs whose LD-2 filings list Emily as an active lobbyist, sorted by activity volume.
Bills they file on
38H.R. 126249 mentions
S. 93245 mentions
H.R. 167236 mentions
S. 86432 mentions
S. 52631 mentions
S. 52731 mentions
S. 109730 mentions
S. 109630 mentions
S. 109530 mentions
H.R. 616630 mentions
H.R. 642330 mentions
H.R. 326928 mentions
S. 227628 mentions
H.R. 648528 mentions
S. 4328 mentions
+ 23 more bills referenced in their activities
Topics in Filings
364Policy topics Emily files on across all their LD-2 activities.
Medical Countermeasure Priority Review Voucher Reauthorization×145
CMMI: GLOBE and GUARD Models×112
National Coverage Determination×87
Antimicrobial Resistance×84
International Pricing Policies×84
Show all 364 topics (+359 more) ▾
R&D Funding for Medical Countermeasures×78
Lowering Drug Costs for American Families Act×77
Preserve Access to Affordable Generics and Biosimilars Act×73
Pharmacy Benefit Manager Transparency Act×72
CMMI Authority×72
Most Favored Nation Drug Pricing Proposals×71
Development and Procurement×70
Prescription Pricing for the People Act×70
Funding for Strategic National Stockpile×69
Stop STALLING Act×68
Pandemic Preparedness×68
Biodefense/Biomedical/Emergency Preparedness Research×66
FY 2026 Appropriations for Agencies×65
Centers for Disease Control and Prevention×65
Health Resources and Services Administration×65
FY 2026 Appropriations for Specific Issues×64
HHS Office of Infectious Disease and HIV/AIDS Policy×64
Interagency Patent Coordination and Improvement Act×56
Administration for Strategic Preparedness and Response×56
Biomedical Advanced Research and Development Authority×56
Pediatric Priority Review Voucher×56
340B Rebate Rule×56
Maintaining Investments and New Innovation×55
Development and Procurement Issues×53
Drug Supply Chain Management×51
Supply Chain Issues×51
Vaccines and Infectious Diseases×51
Clinical Trial Data in China×51
Drug Pricing×50
MCM PRV Reauthorization×42
Food & Drug Administration×42
Big Savings Act×42
Vaccine Injury Compensation Program×40
Risky Research Review Act×36
Quality & Distribution×36
Advanced Manufacturing×36
Drug Shortages×36
Supply Chain Integrity and Traceability×36
Patient Cost-Sharing and Implementation×36
Alternative Payment Arrangements for Gene Therapies×36
Drug Benefit Design×36
National Defense Authorization Act×36
Adult Immunization×36
Vaccine Safety net and Vaccine Infrastructure×36
Value of Vaccines and Vaccine Confidence×36
Pricing and Rebates×35
MCM Manufacturing & Capacity×35
Average Manufacturer Price Calculations×34
Support of Patient Premiums and Cost-Sharing Obligations×34
Orphan Drug Tax Credit×34
Alternative Funding Programs×34
Biosimilar Red Tape Elimination Act×34
SAFE STEP Act×34
Vaccine Injury Compensation Modernization×34
FY 2025 Appropriations×33
Medicare Drug Price Negotiation Act×33
Modernizing and Ensuring PBM Accountability×33
Let Injured Americans Be Legally Empowered×33
Vaccine Access Improvement Act×33
Value-based Contracting and Communications×32
Funding for Women's Health Research×32
Medicaid VBPs for Patients×32
Increasing Transparency in Generic Drug Application×31
Pandemic Preparedness -R&D Funding for Medical Countermeasures×30
Non-Opioid Analgesics Orphan Drug Issues×29
Biosecurity Modernization×29
Centers for Medicare and Medicaid×28
National Institutes of Health×28
Funding for Section 317×28
National Defense Authorization Act 2027×28
Biosimilars Competition×28
Data Privacy Working Group Draft×28
CMMI×28
Pediatric Priority Review Voucher Pandemic Preparedness×28
Restrictions on Intellectual Property Rights×25
FY 2026 Appropriations×24
Value-Based Purchasing×24
Executive Order on Access to Affordable Life-Saving Medications×22
Strengthening Innovation in Medicare and Medicaid Act×22
Biosimilar Copay×21
Interchangeability and Pharmacy Substitution×21
Promising Pathway Act×21
Medicare Part B Physician-Administered Products×21
Maternal Immunization×21
Program Implementation & Oversight×21
Mandating Exclusive Review of Individual Treatments×21
Advanced Research Projects Agency for Health×20
Bio COMPETES×20
PBM Reform×20
Coverage of Accelerated Approval Products×20
Patient Cost-Sharing and Smoothing×20
PROTECT 340B Act×20
Accelerated Approval Artificial Intelligence×19
CICP×19
COVID-19 Pricing Related Provisions×19
Countermeasures Injury Compensation Program×19
Vaccine Safety and Quality×19
VICP Loopholes×19
SUSTAIN 340B Act×19
Prescription Drug User Fee Act×19
Affordable Prescriptions for Patients Act×19
Access to Innovative Treatments Act×19
One Big Beautiful Bill Act×19
MCM PRV Program Reauthorization×18
WHO Pandemic Preparedness Accord Biosimilars×18
Reimbursement Cell & Gene Therapy×18
Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×18
Vaccine and Antimicrobial Resistance Product Development and Incentives×18
Medicaid Drug Rebate Program×18
TRIPS Waiver×17
State Strategic Stockpile Act×17
BIOSECURE Act×17
Biosimilars Red Tape Elimination Act×17
Influenza Planning & Response×17
Project Bioshield×17
American Privacy Rights Act×17
FDA Hiring Flexibility×17
Medication Affordability and Patient Integrity Act×17
DRUG Act×17
FDA Modernization×17
Act 3.0 Medicaid×17
Innovation in Pediatric Drugs Act×17
Retaining Access and Restoring Exclusivity×17
Step Therapy×17
Countermeasure Injury Compensation Fund Amendment Act×17
MCM R&D Incentives×17
Vaccine Quality Measure×17
Vaccine Safety×17
Pandemic Flu×17
American Innovation and Jobs Act×17
Expensing of R&D Expenditures×17
Diversity & Inclusion×16
Compounded Medicines×16
ORPHAN Cures Act×16
CFIUS and Foreign Investment Drug Pricing×16
Genetic Resources, and Associated Traditional Knowledge×16
Decentralized Clinical Trials Drug Evaluation and Review×16
Precision Medicine Initiative Reimbursement and Coverage of Innovative Products×16
Vaccine Access & Compensation×16
Disease X Act×16
Gain of function×16
SAFE Risky Research Act×16
Generic Drug Entry×16
Generic Drug Application Review Reforms×16
Incentives for Generic Entry Issues×16
Funding for Medical Countermeasures×16
Accelerated Approval Antimicrobial Resistance Artificial Intelligence×16
VICP/CICP Capital Formation Incentives×16
Foreign Drug Data Protection Laws×16
House GOP RFI on Supply Chain×15
White House National Biodefense Strategy×15
China Biotechnology Regulations×15
Treaty on Intellectual Property×15
Coverage and Reimbursement×15
Reference Pricing in Drug Reimbursement×15
Section 232×15
World Intellectual Property Office×15
Section 317 Immunization Program×15
Vaccine Injury Compensation Program 340B Drug Discount Program×15
Compounding Pharmacies×15
Contract Manufacturing Ecosystem in the United States×15
Access to Innovative Treatments×15
PASTEUR ACT×15
WHO Pandemic Preparedness Accord Pandemic Preparedness×15
VICP/CICP Antimicrobial Resistance Biodefense Research×15
Vaccines and Infectious Diseases 340B Drug Discount Program×15
Most Favored Nation in Medicaid×15
NSCEB Recommendations Opioid Crisis×15
Cameron's Law Pandemic Preparedness Research & Development Tax Credit Reforms×15
CMMI Models: GLOBE and GUARD×14
Purple Book Draft×14
Consumer Data Privacy and Security Act×14
Diagnostics and Personalized Medicine Regulation and Oversight×14
PDUFA VII Implementation×14
PDUFA VIII Negotiations Drug Importation Drug Manufacturing×14
NSC/OSTP priorities×14
Nucleic acid synthesis security and biotechnology governance×14
Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products×14
VICP/CICP Biodefense Research×14
CDC Reform×14
FDA Hiring Staffing Drug Importation Drug Manufacturing×14
Tariffs Foreign Drug Data Protection Laws Medicaid×14
Incentives for Domestics Manufacturing Orphan Drug Issues×14
R&D Payroll Credit Vaccines and Infectious Disease×14
Tariffs Foreign Agricultural Biotechnology Laws and Regulations×14
China Synthetic Biotech×14
US-China IP Provisions United Nations World Trade Organization×14
Monoclonal Antibody Coverage and Utilization×12
SUPPORT Act×8
Give Kids a Chance Act×7
Tropical Disease Priority Review Voucher×6
Safe, and Secure American Bioeconomy×6
Pediatric Priority Review Voucher Program×6
HELP Copays Act×6
Gene Editing×6
MCM PRV Program×6
HHS Reorganization×6
Prescription Drug Price Relief Act×6
Patent Thickets×5
Non-Opioid Analgesics×5
Temporarily Refundable R&D Credit×5
WHO Pandemic Preparedness Accord×5
Administration Rebate Rule×5
Protected Classes×5
ASPR×5
Orphan Drug Issues×5
Rural Development×4
Food and Drug Administration, and Related Agencies Appropriations Act×4
FY 2026 Appropriations Funding for Antimicrobial Resistance×4
Decentralized Clinical Trials×4
FDA Hiring Flexibility Drug Importation Drug Manufacturing×4
Lower Costs×4
340B Accountability Act×4
Most Favored Nation×4
Fair Prescription Drug Prices for Americans Act×4
National Institute of Health×4
Creating Hope Reauthorization×4
Emerging New Threats and×4
Finding Orphan-Disease Remedies with Antifungal Research and Development×4
National Defense Authorization Act 2026×4
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance×3
Reasonable Pricing Clauses in BARDA Contracts×3
House GOP RFI on Data Privacy×3
COVID-19 Lessons Learned×3
MCM PRV×3
Coverage and Reimbursement Orphan Drug Issues×3
Orphan Drug Tax Credit Pandemic Preparedness×3
Medical Countermeasures PRV Reauthorization×3
Executive Order on Achieving Efficiency Through State and Local Preparedness×3
BSUFA Negotiations×3
Compounded Medicines Drug Patenting×3
Global Fairness in Drug Pricing Act×3
PPRV×3
Bill to address patent thickets×3
Medicare Negotiation and Competitive Licensing Act×3
BARDA×3
American Innovation and R&D Competitiveness Act×3
Farm Bill Reauthorization×2
FDA Approvals×2
Guidance, & Regulations×2
Biomass Crop Assistance, and Biorefineries×2
Office of Biopesticides and Pollution Prevention Division×2
Biotechnology and Agriculture Trade Program×2
Farm Bill Programs Energy Title IX×2
NextGen Aircraft Technology×2
Fuels & Metrics×2
340B Drug Discount Program×2
Biosecurity Infrastructure for Operational×2
NDAA×2
MINI Act×2
Climate Change×2
VICP×2
Medicaid Drug Rebate Program Rule×2
More Cures Act×2
Biodefense Research×2
Funding for Biodefense/Biomedical/Emergency Preparedness Research×2
Protecting Americans Data from Foreign Adversaries Act×2
B5 Coalition on Supply Chain Resiliency×2
Cell & Gene Therapy×2
Most Favored Nation Foreign Drug Data Protection Laws×2
Project Bio Shield×2
Improving Data Accessibility Through Advancements×2
Drug Evaluation and Review×2
Drug Importation Drug Manufacturing×2
Stronger Patents Act×2
Protecting Patient Access to Cancer and Therapies×2
More Transparency Act×2
VICP CICP×2
Family Vaccine Protection Act×2
ASPR FY 2026 Appropriations for Specific Issues×2
Helping Startups Continue to Grow Act×2
Small Entity Update Act×2
Expanding Access to Capital Act×2
Equal Opportunity for All Investors Act×2
R&D Payroll Credit×2
Net Operating Loss×2
Vaccines and Infectious Disease×2
National Institutes of Health FY 2026 Appropriations for Specific Issues×2
Avian Flu Farm Bill×1
Genetically Engineered×1
Climate Issues & impact on the agriculture and food sectors×1
Efficient Science-Based Review of Biotech Products×1
International Consistency of Regulations×1
Funding for Antimicrobial Resistance×1
FY 2026 Appropriations Pandemic Preparedness×1
Bioenergy Technology Office×1
Environmental Energy R&D×1
Program & Oversight×1
American Pandemic Preparedness Plan×1
FY 2026 Appropriations Data Privacy×1
Clinical Trial Diversity Drug Evaluation and Review×1
CICP Funding for FDA×1
User Fees Funding for Health Resources and Services Administration×1
Funding for Womens Health Research International Reference Pricing Medicaid×1
Womens Health Research Pandemic Preparedness×1
General Cell & Gene Therapy×1
FY 2026 Appropriations Clinical Trial Data in China Data Privacy×1
General Diversity & Inclusion×1
Clinical Trial Diversity×1
General Drug Evaluation and Review×1
FY2025 Appropriations×1
PBN Reform×1
International Reference Pricing Foreign Drug Data Protection Laws×1
Regulatory Harmonization Funding for Antimicrobial Resistance×1
FY 2026 Appropriations International Reference Pricing Issues×1
Innovation and Pediatric Drugs Act×1
EU Ag-Biotech Policies×1
International Consistency of Regulation for Gene Edited Products×1
Korea Biotechnology Regulations×1
Medical Supply Chain Resiliency Act×1
Synthetic Biotech Pharmaceutical and Ag Biotech Tariffs US-China Trade Agreement×1
Ag-Biotech Provisions×1
IP Provisions World Health Organization×1
WHO Pandemic Preparedness Accord World Intellectual Property Office×1
Patent Thickets Drug Pricing×1
Regulatory Harmonization Medicaid×1
Department of Energy×1
Department of Transportation×1
USDA FY 2026 Appropriations for Specific Issues×1
Environment and Energy R&D×1
Renewable Materials/BIO-based Products×1
BARDA FY 2026 Appropriations for Specific Issues×1
Section 317 Immunization Program 340B Drug Discount Program×1
Accelerated Approval Access to non-human Primates×1
Climate Change Data Privacy×1
PDUFA×1
FDA Reform×1
Compounding & Counterfeit Medicines Drug Patenting×1
Rare Disease Pilot Program Pandemic Preparedness×1
End Price Gauging for Medications Act×1
SMART Prices Act×1
VICP Biofuels and SAF×1
Incentives for Sustainable Aviation Fuels×1
Sustainable Aviation Fuels Tax Credit×1
Carbo Capture Utilization Parity Capital Formation Incentives×1
American Innovation Act×1
National Institute of Health FY 2026 Appropriations for Specific Issues×1
Reimbursement Cell & Gene Therapy Data Privacy×1
Clinical Trial Modernization×1
Drug Rebate Program Rule×1
HHS Reorganization CDC Reform×1
Prescription Drug Pricing for the People Act×1
Most Favored Nation Foreign Agricultural Biotechnology Laws and Regulations×1
China Synthetic Biotech Tariffs Trade Relations×1
340B ACCESS Act×1
Synthetic Nucleic Acid Synthesis Screening×1
PDUFA VIII Negotiations×1
Drug Manufacturing×1
Biologics Competition Act×1
Enhanced Access to Affordable Medicines Act×1
Most Favored Nation Pricing Opioid Crisis×1
Reimbursement and Coverage of Innovative Products×1
Administrative Rebate Rule×1
MCM PRV Program CDC Reform×1
340B Rebate Pilot Program×1
FDA Hiring Flexibility Drug Manufacturing×1
Most Favored Nation Pricing×1
Vaccine Access×1
Vaccines for Children Program×1
Pulled from the org’s own LD-2 disclosures. See the source filings ↓
Issue mix
LDA general-issue codes weighted by activity count.
Health Issues18
Medical/Disease Research/Clinical Labs18
Medicare/Medicaid18
Budget/Appropriations17
Homeland Security17
Taxation/Internal Revenue Code17
Trade (domestic/foreign)16
Animals1